Trial reportJournal of medicinal food2015
Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults.
Trial report in Journal of medicinal food, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01858376 (Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Clinical effects of Emblica officinalis fruit consumption on cardiovascular disease risk factors: a systematic review and meta-analysis.BMC complementary medicine and therapies · 2023Pooled it
- Potential effect of tropical fruits Phyllanthus emblica L. for the prevention and management of type 2 diabetic complications: a systematic review of recent advances.European journal of nutrition · 2021Pooled it
- Effects of 12 Weeks of Chromium,Nutrients · 2025Trial
- Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study.BMC complementary and alternative medicine · 2019Trial
- The Human Skeletal Muscle Transcriptome in Response to Oral Shilajit Supplementation.Journal of medicinal food · 2016Trial
- Edible Berries-An Update on Nutritional Composition and Health Benefits-Part II.Current nutrition reports · 2025Review
- The Efficacy and Safety ofActa medica Philippina · 2023Article
- Extraction, Characterization, and Platelet Inhibitory Effects of Two Polysaccharides from the Cs-4 Fungus.International journal of molecular sciences · 2022Article
- Functional and Nutraceutical Significance of Amla (Antioxidants (Basel, Switzerland) · 2022Review
- Evaluation of a Polyherbal Formulation on the Management of Migraine Headaches due to Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Molecular Mechanisms of Cancer Prevention by Gooseberry (Nutrition and cancer · 2022Review
- Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study.Contemporary clinical trials communications · 2020Article
- Evaluation of the Effect of Fish Oil Alone and in Combination with a Proprietary Chromium Complex on Endothelial Dysfunction, Systemic Inflammation and Lipid Profile in Type 2 Diabetes Mellitus - A Randomized, Double-Blind, Placebo-Controlled Clinical Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Recent Developments in the Reduction of Oxidative Stress through Antioxidant Polymeric Formulations.Pharmaceutics · 2019Review
- Traditional tonifying polyherbal infusion, Jatu-Phala-Tiga, exerts antioxidant activities and extends lifespan of Caenorhabditis elegans.BMC complementary and alternative medicine · 2019Article
- Inhibition of LPS-Induced Oxidative Damages and Potential Anti-Inflammatory Effects ofAntioxidants (Basel, Switzerland) · 2019Article
- A systematic review on the cardiovascular pharmacology ofJournal of cardiovascular and thoracic research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS(®)) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.